US 10040766
Ubiquitination inhibitors
granted A61PA61P19/00A61P25/00
Quick answer
US patent 10040766 (Ubiquitination inhibitors) held by Rigel Pharmaceuticals, Inc. expires Mon Aug 02 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Rigel Pharmaceuticals, Inc.
- Grant date
- Tue Aug 07 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Aug 02 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 16
- CPC classes
- A61P, A61P19/00, A61P25/00, A61P29/00, A61P35/00